Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial by Pinto, Carmine, MD, Zucali, Paolo Andrea, MD, Pagano, Maria, MD, Grosso, Federica, MD, Pasello, Giulia, MD, Garassino, Marina Chiara, MD, Tiseo, Marcello, MD, Soto Parra, Hector, MD, Grossi, Francesco, MD, Cappuzzo, Federico, MD, de Marinis, Filippo, MD, Pedrazzoli, Paolo, MD, Bonomi, Maria, MD, Gianoncelli, Letizia, MD, Perrino, Matteo, MD, Santoro, Armando, MD, Zanelli, Francesca, MD, Bonelli, Candida, MD, Maconi, Antonio, MD, Frega, Stefano, MD, Gervasi, Erika, MD, Boni, Luca, MD, Ceresoli, Giovanni Luca, MD

Get full text